Epilepsy

Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing

Retrieved on: 
Friday, February 9, 2024

‍TRUMBULL, Conn. and EL MONTE, Calif., Feb. 9, 2024 /PRNewswire/ -- CooperSurgical®, a global leader in fertility and women's health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels.

Key Points: 
  • CBR Portrait includes more than twice as many genes as CBR Snapshot and may identify more rare causes of these conditions.
  • CBR Landscape also includes a pharmacogenetic (PGx) component, which is a type of genetic testing that can determine how a person breaks down or metabolizes certain medications.
  • "Part of our mission is to use our resources and testing to improve the lives of those around us.
  • Newborn genetic analysis serves as an illustration of this commitment, as early intervention may significantly improve health outcomes for many of these conditions."

Seizure Action Plan Awareness Week Set For February 12-19

Retrieved on: 
Wednesday, February 7, 2024

BATON ROUGE, La., Feb. 7, 2024 /PRNewswire/ -- The Seizure Action Plan Coalition , a collaboration managed by Epilepsy Alliance America , will hold the 4th Annual Seizure Action Plan (SAP) Awareness Week Feb. 12-19, 2024.

Key Points: 
  • BATON ROUGE, La., Feb. 7, 2024 /PRNewswire/ -- The Seizure Action Plan Coalition , a collaboration managed by Epilepsy Alliance America , will hold the 4th Annual Seizure Action Plan (SAP) Awareness Week Feb. 12-19, 2024.
  • Let's unite to raise awareness during Seizure Action Plan Awareness Week," said Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes.
  • The Seizure Action Plan Coalition website has tools and resources from its awareness partners for individuals with epilepsy and their families.
  • For more information on Seizure Action Plan Awareness Week, visit SeizureActionPlans.org today.

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Tuesday, February 6, 2024

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m.

Key Points: 
  • NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m.
  • ET.
  • A live webcast of the Oppenheimer presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com .
  • An archived replay of the webcast will be available on the Company’s website following the live presentation for approximately 90 days.

Mahalo Banking Reimagines the Software Development Toolkit (SDK)

Retrieved on: 
Tuesday, February 6, 2024

To ensure compatibility with the latest development technologies, the SDK supports all development languages as well as both local and cloud-based network environments.

Key Points: 
  • To ensure compatibility with the latest development technologies, the SDK supports all development languages as well as both local and cloud-based network environments.
  • “With the launch of our reimagined SDK, Mahalo is setting new standards for customization in the financial technology landscape,” said Daniel Domek, CTO at Mahalo.
  • “The integration of our SDK with a supporting Neurodiverse Platform Technology is a significant milestone,” said Jim Stickley, CEO at Mahalo.
  • With a focus on innovation, Mahalo strives to create inclusive, adaptable, and personalized financial experiences for all users.

Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan

Retrieved on: 
Thursday, January 18, 2024

TOKYO, Jan 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.

Key Points: 
  • TOKYO, Jan 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.
  • Fycompa is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories.
  • Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation.
  • Since Fycompa is the only AMPA receptor antagonist-based AED, Eisai developed this injection formulation to meet the needs of patients who are unable to use oral administration, and filed a supplementary new drug application as a new route of administration in August 2022, leading to this approval.

The 12th Annual Joseph Chung Scholarship Awards Nearly Half a Million Dollars to Students

Retrieved on: 
Thursday, February 1, 2024

Vancouver, BC, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The Joseph Chung Scholarship Fund, part of the philanthropy division at Primacorp Ventures Inc., awarded 201 students at its 12th annual Ceremony on Saturday, January 27.

Key Points: 
  • Vancouver, BC, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The Joseph Chung Scholarship Fund, part of the philanthropy division at Primacorp Ventures Inc., awarded 201 students at its 12th annual Ceremony on Saturday, January 27.
  • A total of nearly $475,000 was given to scholarship recipients across the province to pursue post-secondary education.
  • Dr. Peter and Stephanie Chung established the Scholarship Fund in honour of their late son, Joseph, who died unexpectedly at 32.
  • As an inspiration for the students and everyone in the audience, the ceremony featured two former scholarship recipients who shared how the Joseph Chung Scholarship has shaped their lives and relationship with God.

Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal

Retrieved on: 
Thursday, February 1, 2024

PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.

Key Points: 
  • PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.
  • In conjunction with the Series B financing, Proniras has appointed Steven Gillis, Ph.D., as Chairman and Atul Saran as an independent member to the Company’s Board of Directors.
  • "Their wealth of knowledge and industry experience will be instrumental in guiding Proniras through its next phase of growth.
  • We look forward to their leadership and contributions as we continue to advance Proniras through the next stages of product development."

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 2, 2024

The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.

Key Points: 
  • The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.
  • The spinal cord stimulation segment accounted for the largest share of the neuromodulation market, by internal neuromodulation type, in 2022.
  • Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    Key Market Players of Neuromodulation Industry:
    The break-up of the profile of primary participants in the neuromodulation market:
    Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=921
    Neuromodulation Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the neuromodulation market across varied regions.

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 2, 2024

The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.

Key Points: 
  • The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.
  • In 2022, internal neuromodulation dominated the global neuromodulation market.
  • The spinal cord stimulation segment accounted for the largest share of the neuromodulation market, by internal neuromodulation type, in 2022.
  • Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    Key Market Players of Neuromodulation Industry:
    The break-up of the profile of primary participants in the neuromodulation market:
    Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=921
    Neuromodulation Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments.

Minyard Morris Announces Janani S. Rana as First Female Partner

Retrieved on: 
Thursday, February 1, 2024

NEWPORT BEACH, Calif., Feb. 1, 2024 /PRNewswire-PRWeb/ -- Janani S. Rana has been announced the sixth partner at Minyard Morris, a Newport Beach, California-based family law firm. Janani is the firm's first female partner, marking a significant stride in the distinguished firm's history. Janani is a Certified Family Law Specialist and experienced trial attorney who handles complex family law issues and high net worth matters.

Key Points: 
  • Janani is the firm's first female partner, marking a significant stride in the distinguished firm's history.
  • E. Minyard, Founding Partner, Minyard Morris
    "Janani has an ownership mentality, and she is interested in helping improve every aspect of the firm to benefit our clients and our people," said Mark.
  • E. Minyard, Founding Partner, Minyard Morris .
  • Janani joined Minyard Morris in 2016 after working in family law for seven years in Los Angeles County.